High dose D-serine in the treatment of schizophrenia

https://doi.org/10.1016/j.schres.2010.05.012Get rights and content

Abstract

Background

D-serine is an allosteric modulator of the brain N-methyl-d-aspartate (NMDA) receptor and a potential novel treatment of schizophrenia. Double-blind studies have been performed at 30 mg/kg/day (∼ 2 g/day) with encouraging results, but no formal dose escalation studies have been performed. We describe the first evaluation of the efficacy and safety of d-serine at doses > 30 mg/kg/day; a 4-week, open-label trial of adjunctive D-serine (30, 60 or 120 mg/kg/day).

Methods

42 antipsychotic-stabilized patients with schizophrenia or schizoaffective disorder participated. PANSS was obtained bi-weekly and neuropsychological (MATRICS) was obtained pre- and post medication phase. The pharmacokinetics/pharmacodynamics (PK/PD), and safety of doses  30 mg/kg was also evaluated.

Results

Significant improvement in symptoms and neuropsychological measures was noted across doses. On the PANSS, improvement was observed for positive (p = 0.006;d = 0.46), negative (p < 0.001;d = 0.68), general (p = 0.001;d = 0.53), and total (p < 0.0001;d = 0.74) symptoms. On MATRICS, while only non-significant improvement was noted at 30 mg/kg, highly significant, large effect size improvement was noted on the composite score (p < 0.01;d=1.0) for doses  60 mg/kg, leading to a significant dose-by-time interaction (p < 0.01).

In PK analyses, significant dose-dependent increases in plasma D-serine levels were seen during the study, predictive of significantly increased brain levels. Furthermore, increases in plasma levels correlated with improved symptomatic and neuropsychological function.

Discussion

These findings support double-blind investigation of D-serine at doses  60 mg/kg/d, and suggest effectiveness in treatment of both persistent symptoms and neurocognitive dysfunction.

Introduction

Phencyclidine (PCP) and related compounds induce a psychotic state that closely resembles schizophrenia by blocking N-methyl-d-aspartate (NMDA)-type glutamate receptors (Javitt and Zukin, 1991). Agonists of the NMDA positive allosteric modulatory site, such as glycine and D-serine, reverse behavioral effects of PCP preclinically, suggesting potential therapeutic utility. Disturbances in D-serine metabolism are also reported (Kantrowitz and Javitt, 2009). To date, several studies of D-serine in schizophrenia have been conducted using a dose of ∼ 30 mg/kg with positive results across studies (Javitt, 2008). Nevertheless, ideal doses of D-serine in clinical studies remains to be determined. In this study, we evaluated clinical effects of D-serine at doses > 30 mg/kg/d with emphasis on both safety and efficacy.

Section snippets

Inclusion criteria

1) Aged 18-60; 2) SCID diagnosis of schizophrenia/schizoaffective disorder (First, et al., 1997); 3) Positive and Negative Symptom Scale (PANSS) (Kay, et al., 1987) negative symptom score > 20 and total score between 60-110; 4) Stable Clinical Global Impression Scale (CGI) (Guy, 1976) for two consecutive weeks; 5) Simpson Angus Scale (SAS) (Simpson and Angus, 1970) score ≤ 12; 6) Calgary Depression Inventory for Schizophrenia (CDDS) (Addington, et al., 1994) score ≤ 10 and suicide less than

PANSS

Across doses, significant, moderate effect-size improvements were observed on PANSS total and subscales (Fig. 1 a-d and Supplement 1). Significant improvement was seen on the total PANSS within all three phases (p < 0.05), and across all three subscales for the 120 mg/kg dose.

MATRICS

Baseline scores were ∼ 2 sd below normative levels on the MATRICS, suggesting clinically significant baseline cognitive deficits (Fig. 2). There were no significant differences in baseline mean composite (F2,44= 1.5;p = 0.23) or

Discussion

Similar to prior studies (Javitt, 2008), significant improvement was observed on PANSS positive, negative and total scores. Significant baseline correlations were observed between reduced D-serine levels and negative symptoms and between peak D-serine on day 1 and subsequent improvement in negative symptoms, consistent with prior clinical findings (Neeman et al., 2005, Sumiyoshi et al., 2004). As plasma D-serine levels were unknown at the time when ratings were performed, these are unlikely to

Role of funding source

This project was funded by NIH grant (U01 MH074356). Preclinical/clinical toxicology in support of the project was provided by 5R44AT000810 and a grant from the Stanley Foundation. The NIH and Stanley Foundation had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the paper for publication.

Contributors

Dr. Javitt, Woods, Malhotra, Cornblatt and D'Souza designed the study. Dr. Kantrowitz, Woods and Javitt performed the statistical analysis. Ms. Balla and Dr. Suckow performed the plasma D-serine analysis. Ms. Silipo and Dr. Saska coordinated patient recruitment. Dr. Kantrowitz wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.

Conflict of Interest

Daniel Javitt holds intellectual property rights for use of glycine, D-serine, and glycine transport inhibitors in the treatment of schizophrenia; he is a major shareholder in Glytech and Amino Acid Solutions; he has received consulting payments from Glytech. Scott Woods has received a use patent for a different indication; royalties devolve to Yale University to further his research and not to him personally. All of the other authors have no potential conflicts of interest relevant to this

Acknowledgments

Funded by NIH grant (U01 MH074356) to DCJ.

References (19)

There are more references available in the full text version of this article.

Cited by (206)

  • A narrative review of treatment interventions to improve cognitive performance in schizophrenia, with an emphasis on at-risk and early course stages

    2022, Psychiatry Research
    Citation Excerpt :

    Numerous clinical trials have been performed utilizing NMDA receptor agonists (glycine and D‑serine), the NMDA receptor partial agonist, d-cycloserine (Coyle and Tsai, 2004), and GlyT1 inhibitors (e.g., sarcosine and bitopertin) (Chang et al., 2020; Umbricht et al., 2014a). Initial studies showed improvement in cognitive function with NMDA receptor enhancers as an adjunct treatment to conventional antipsychotic drugs (Goff et al., 1999; Heresco-Levy et al., 1996, 1998; Kantrowitz et al., 2010; Tsai et al., 1998). Furthermore, a recent phase 2 trial found that 12 weeks of treatment with a GlyT1 inhibitor, BI 425,809, improved cognition in 509 patients with SCZ (Fleischhacker et al., 2021).

View all citing articles on Scopus
View full text